Cyclosporin A in the treatment of CLL associated PRCA and bone marrow hypoplasia.
Three patients (1 PRCA-T-CLL, 1 PRCA-B-CLL, 1 B-CLL aplasia) were treated with cyclosporin A (CS-A). Patient no 1 had relapsed during steroid therapy and the remaining two patients had been resistant to conventional immunosuppression. CS-A produced in all cases a prompt remission (within 1-4 weeks) of bone marrow failure. Mild reversible renal toxicity was the only side-effect noted. CS-A might be tried in every case of CLL-associated bone marrow failure.
Tura
S
S
Institute of Haematology L. e A. Serágnoli, University of Bologna, Italy.
Finelli
C
C
Bandini
G
G
Cavo
M
M
Gobbi
M
M
D000328:Adult; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D003524:Cyclosporins / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications*; D015461:Leukemia, Prolymphocytic, T-Cell / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy* / Q000209:etiology
D003524:Cyclosporins